-
Something wrong with this record ?
Chemical angioplasty with spasmolytics for vasospasm after subarachnoid hemorrhage
A. Hejčl, F. Cihlář, V. Smolka, P. Vachata, R. Bartoš, J. Procházka, J. Cihlář, M. Sameš,
Language English Country Austria
Document type Journal Article
Grant support
NT13883
MZ0
CEP Register
NLK
ProQuest Central
from 1997-01-01
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01
Springer Nature OA/Free Journals
from 1950-02-01
- MeSH
- Angioplasty adverse effects methods MeSH
- Adult MeSH
- Infusions, Intra-Arterial adverse effects MeSH
- Vasospasm, Intracranial drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Nimodipine administration & dosage therapeutic use MeSH
- Subarachnoid Hemorrhage drug therapy MeSH
- Vasodilator Agents administration & dosage therapeutic use MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Clinically symptomatic vasospasm leading to delayed ischemic neurological deficits occurs in up to 30% of patients with subarachnoid hemorrhage (SAH). Vasospasm can result in a serious decline in clinical conditions of patients with SAH, yet the algorithm for vasospasm treatment and prevention remains unclear. Intra-arterial administration of vasodilators is one of the modalities used for vasospasm therapy. METHODS: Over the last 7 years, we have treated 27 female and 7 male patients with vasospasm using intra-arterial administration of either nimodipine or milrinone; all had suffered aneurysm rupture. Of these patients, 28 were treated surgically (clip), and 6 patients had their aneurysm coiled. Spasmolytics were applied from day 2 to day 18 after rupture. RESULTS: Of the 53 procedures, angiographic improvement was documented in 92% of cases with a mean flow velocity decrease of 65 cm/s. Brain metabolism changes were monitored after the procedure. The highest level of immediate clinical improvement was observed in conscious patients with a focal neurological deficit (aphasia, hemiparesis). Overall clinical outcomes (Glasgow outcome scale, GOS) were as follows: GOS 5 (12 patients), GOS 4 (5 patients), GOS 3 (5 patients), GOS 2 (6 patients), and GOS 1 (6 patients). CONCLUSIONS: Intra-arterial administration of spasmolytics is a safe and potent method of vasospasm treatment. It is most effective when applied to conscious patients with a focal deficit. For unconscious patients, its therapeutic benefits are inconclusive. Patients in severe clinical states would further require use of other diagnostic tools such as multimodal brain monitoring to complement vasospasm therapy.
Department of Mathematics Faculty of Science J E Purkinje University Ústí nad Labem Czech Republic
Department of Radiology Masaryk Hospital Ústí nad Labem Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031022
- 003
- CZ-PrNML
- 005
- 20181214104827.0
- 007
- ta
- 008
- 171025s2017 au f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00701-017-3104-5 $2 doi
- 035 __
- $a (PubMed)28224318
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a au
- 100 1_
- $a Hejčl, Aleš, $u Department of Neurosurgery of the J.E. Purkinje University, Masaryk Hospital, Sociální péče 12A, Ústí nad Labem, 401 13, Czech Republic. ales.hejcl@gmail.com. International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. ales.hejcl@gmail.com. Department of Neurosurgery of the 1st Medical Faculty and the Central Military Hospital, Prague, Czech Republic. ales.hejcl@gmail.com. Department of Tissue Culture and Stem Cells, Institute of Experimental Medicine ASCR, Prague, Czech Republic. ales.hejcl@gmail.com. $d 1978- $7 xx0077402
- 245 10
- $a Chemical angioplasty with spasmolytics for vasospasm after subarachnoid hemorrhage / $c A. Hejčl, F. Cihlář, V. Smolka, P. Vachata, R. Bartoš, J. Procházka, J. Cihlář, M. Sameš,
- 520 9_
- $a BACKGROUND: Clinically symptomatic vasospasm leading to delayed ischemic neurological deficits occurs in up to 30% of patients with subarachnoid hemorrhage (SAH). Vasospasm can result in a serious decline in clinical conditions of patients with SAH, yet the algorithm for vasospasm treatment and prevention remains unclear. Intra-arterial administration of vasodilators is one of the modalities used for vasospasm therapy. METHODS: Over the last 7 years, we have treated 27 female and 7 male patients with vasospasm using intra-arterial administration of either nimodipine or milrinone; all had suffered aneurysm rupture. Of these patients, 28 were treated surgically (clip), and 6 patients had their aneurysm coiled. Spasmolytics were applied from day 2 to day 18 after rupture. RESULTS: Of the 53 procedures, angiographic improvement was documented in 92% of cases with a mean flow velocity decrease of 65 cm/s. Brain metabolism changes were monitored after the procedure. The highest level of immediate clinical improvement was observed in conscious patients with a focal neurological deficit (aphasia, hemiparesis). Overall clinical outcomes (Glasgow outcome scale, GOS) were as follows: GOS 5 (12 patients), GOS 4 (5 patients), GOS 3 (5 patients), GOS 2 (6 patients), and GOS 1 (6 patients). CONCLUSIONS: Intra-arterial administration of spasmolytics is a safe and potent method of vasospasm treatment. It is most effective when applied to conscious patients with a focal deficit. For unconscious patients, its therapeutic benefits are inconclusive. Patients in severe clinical states would further require use of other diagnostic tools such as multimodal brain monitoring to complement vasospasm therapy.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a angioplastika $x škodlivé účinky $x metody $7 D017130
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intraarteriální infuze $x škodlivé účinky $7 D007261
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nimodipin $x aplikace a dávkování $x terapeutické užití $7 D009553
- 650 _2
- $a subarachnoidální krvácení $x farmakoterapie $7 D013345
- 650 _2
- $a vazodilatancia $x aplikace a dávkování $x terapeutické užití $7 D014665
- 650 _2
- $a intrakraniální vazospazmus $x farmakoterapie $7 D020301
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Cihlář, Filip $u Department of Radiology, Masaryk Hospital, Ústí nad Labem, Czech Republic. $7 xx0232583
- 700 1_
- $a Smolka, Vojtěch $u Department of Radiology, Masaryk Hospital, Ústí nad Labem, Czech Republic. $7 xx0237397
- 700 1_
- $a Vachata, Petr, $u Department of Neurosurgery of the J.E. Purkinje University, Masaryk Hospital, Sociální péče 12A, Ústí nad Labem, 401 13, Czech Republic. Department of Neurosurgery, University Hospital Pilsen, The Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic. $d 1973- $7 nlk20020123493
- 700 1_
- $a Bartoš, Robert, $u Department of Neurosurgery of the J.E. Purkinje University, Masaryk Hospital, Sociální péče 12A, Ústí nad Labem, 401 13, Czech Republic. $d 1974- $7 nlk20020123486
- 700 1_
- $a Procházka, Jan, $u Department of Anesthesiology, Perioperative Medicine and Intensive Care, J.E. Purkinje University, Masaryk Hospital, Ústí nad Labem, Czech Republic. $d 1960 leden 20.- $7 nlk20020123489
- 700 1_
- $a Cihlář, Jiří $u Department of Mathematics, Faculty of Science, J.E. Purkinje University, Ústí nad Labem, Czech Republic. $7 _AN063258
- 700 1_
- $a Sameš, Martin, $u Department of Neurosurgery of the J.E. Purkinje University, Masaryk Hospital, Sociální péče 12A, Ústí nad Labem, 401 13, Czech Republic. $d 1963- $7 nlk20020123488
- 773 0_
- $w MED00009022 $t Acta neurochirurgica $x 0942-0940 $g Roč. 159, č. 4 (2017), s. 713-720
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28224318 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20181214104953 $b ABA008
- 999 __
- $a ok $b bmc $g 1254615 $s 992049
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 159 $c 4 $d 713-720 $e 20170221 $i 0942-0940 $m Acta neurochirurgica $n Acta Neurochir $x MED00009022
- GRA __
- $a NT13883 $p MZ0
- LZP __
- $a Pubmed-20171025